{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:51:54Z","timestamp":1792857114097,"version":"4.5.0"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04029-y","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T06:19:41Z","timestamp":1740982781000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Immunomodulatory effects of mesenchymal stem cell therapy in chronic kidney disease: a literature review"],"prefix":"10.1186","volume":"26","author":[{"given":"Jipeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"issue":"10302","key":"4029_CR1","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","volume":"398","author":"K Kalantar-Zadeh","year":"2021","unstructured":"Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021;398(10302):786\u2013802.","journal-title":"Lancet"},{"issue":"10225","key":"4029_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"Collaboration GBDCKD; Global","year":"2020","unstructured":"Collaboration GBDCKD; Global. regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709\u201333.","journal-title":"Lancet"},{"issue":"10159","key":"4029_CR3","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","volume":"392","author":"KJ Foreman","year":"2018","unstructured":"Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016\u201340 for 195 countries and territories. Lancet. 2018;392(10159):2052\u201390.","journal-title":"Lancet"},{"issue":"9981","key":"4029_CR4","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/S0140-6736(14)61601-9","volume":"385","author":"T Liyanage","year":"2015","unstructured":"Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385(9981):1975\u201382.","journal-title":"Lancet"},{"issue":"1","key":"4029_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2337\/dc20-1913","volume":"44","author":"HT Cheng","year":"2021","unstructured":"Cheng HT, Xu X, Lim PS, Hung KY. Worldwide Epidemiology of Diabetes-Related End-Stage Renal Disease, 2000\u20132015. Diabetes Care. 2021;44(1):89\u201397.","journal-title":"Diabetes Care"},{"issue":"11","key":"4029_CR6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.15585\/mmwr.mm7111a3","volume":"71","author":"NR Burrows","year":"2022","unstructured":"Burrows NR, Koyama A, Pavkov ME. Reported Cases of End-Stage Kidney Disease - United States, 2000\u20132019. MMWR Morb Mortal Wkly Rep. 2022;71(11):412\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"4029_CR7","doi-asserted-by":"publisher","first-page":"e074216","DOI":"10.1136\/bmj-2022-074216","volume":"383","author":"TK Chen","year":"2023","unstructured":"Chen TK, Hoenig MP, Nitsch D, Grams ME. Advances in the management of chronic kidney disease. BMJ. 2023;383: e074216.","journal-title":"BMJ"},{"issue":"15","key":"4029_CR8","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"key":"4029_CR9","doi-asserted-by":"crossref","unstructured":"The E-KCG, Herrington WG, Staplin N, et al.; Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117\u2013127.","DOI":"10.1056\/NEJMoa2204233"},{"key":"4029_CR10","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S): S117\u2013S314.","DOI":"10.1016\/j.kint.2023.10.018"},{"issue":"10433","key":"4029_CR11","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(23)02843-X","volume":"403","author":"K Wong","year":"2024","unstructured":"Wong K, Pitcher D, Braddon F, et al. Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort. Lancet. 2024;403(10433):1279\u201389.","journal-title":"Lancet"},{"issue":"3","key":"4029_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/stem.269","volume":"28","author":"HK Salem","year":"2010","unstructured":"Salem HK, Thiemermann C. Mesenchymal Stromal Cells: Current Understanding and Clinical Status. Stem Cells. 2010;28(3):585\u201396.","journal-title":"Stem Cells"},{"key":"4029_CR13","doi-asserted-by":"crossref","unstructured":"Li S, Wang Y, Wang Z, et al. Enhanced renoprotective effect of GDNF-modified adipose-derived mesenchymal stem cells on renal interstitial fibrosis. Stem Cell Res Ther. 2021;12(1):27.","DOI":"10.1186\/s13287-020-02049-z"},{"issue":"11","key":"4029_CR14","doi-asserted-by":"publisher","first-page":"5248","DOI":"10.7150\/thno.54550","volume":"11","author":"J-Y Cao","year":"2021","unstructured":"Cao J-Y, Wang B, Tang T-T, et al. Exosomal miR-125b-5p deriving from mesenchymal stem cells promotes tubular repair by suppression of p53 in ischemic acute kidney injury. Theranostics. 2021;11(11):5248\u201366.","journal-title":"Theranostics"},{"key":"4029_CR15","doi-asserted-by":"crossref","unstructured":"Torrico S, Hotter G, Jativa S. Development of cell therapies for renal disease and regenerative medicine. Int J Mol Sci. 2022;23(24):15943.","DOI":"10.3390\/ijms232415943"},{"issue":"9","key":"4029_CR16","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1002\/sctm.19-0419","volume":"10","author":"LJ Hickson","year":"2021","unstructured":"Hickson LJ, Abedalqader T, Ben-Bernard G, et al. A systematic review and meta-analysis of cell-based interventions in experimental diabetic kidney disease. Stem Cells Transl Med. 2021;10(9):1304\u201319.","journal-title":"Stem Cells Transl Med"},{"issue":"7","key":"4029_CR17","doi-asserted-by":"publisher","first-page":"F1064","DOI":"10.1152\/ajprenal.00178.2013","volume":"305","author":"N Liu","year":"2013","unstructured":"Liu N, Patzak A, Zhang J. CXCR4-overexpressing bone marrow-derived mesenchymal stem cells improve repair of acute kidney injury. American Journal of Physiology-Renal Physiology. 2013;305(7):F1064\u201373.","journal-title":"American Journal of Physiology-Renal Physiology"},{"issue":"10","key":"4029_CR18","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.stem.2021.09.001","volume":"28","author":"H Soliman","year":"2021","unstructured":"Soliman H, Theret M, Scott W, et al. Multipotent stromal cells: One name, multiple identities. Cell Stem Cell. 2021;28(10):1690\u2013707.","journal-title":"Cell Stem Cell"},{"issue":"3","key":"4029_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1089\/scd.2008.0097","volume":"18","author":"S Choi","year":"2009","unstructured":"Choi S, Park M, Kim J, Hwang S, Park S, Lee Y. The role of mesenchymal stem cells in the functional improvement of chronic renal failure. Stem Cells Dev. 2009;18(3):521\u20139.","journal-title":"Stem Cells Dev"},{"issue":"1","key":"4029_CR20","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1021\/acsnano.0c08947","volume":"15","author":"M Zhao","year":"2021","unstructured":"Zhao M, Liu S, Wang C, et al. Mesenchymal Stem Cell-Derived Extracellular Vesicles Attenuate Mitochondrial Damage and Inflammation by Stabilizing Mitochondrial DNA. ACS Nano. 2021;15(1):1519\u201338.","journal-title":"ACS Nano"},{"key":"4029_CR21","doi-asserted-by":"crossref","unstructured":"Birtwistle L, Chen X-M, Pollock C. Mesenchymal stem cell-derived extracellular vesicles to the rescue of renal injury. Int J Mol Sci. 2021;22(12):6596.","DOI":"10.3390\/ijms22126596"},{"issue":"4","key":"4029_CR22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.bj.2021.07.009","volume":"45","author":"A Almeida","year":"2022","unstructured":"Almeida A, Lira R, Oliveira M, et al. Bone marrow-derived mesenchymal stem cells transplantation ameliorates renal injury through anti-fibrotic and anti-inflammatory effects in chronic experimental renovascular disease. Biomed J. 2022;45(4):629\u201341.","journal-title":"Biomed J"},{"issue":"8","key":"4029_CR23","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1002\/art.27548","volume":"62","author":"L Sun","year":"2010","unstructured":"Sun L, Wang D, Liang J, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 2010;62(8):2467\u201375.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"4029_CR24","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/ard.2009.123463","volume":"69","author":"J Liang","year":"2010","unstructured":"Liang J, Zhang H, Hua B, et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis. 2010;69(8):1423\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"4029_CR25","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/j.1440-1797.2012.01622.x","volume":"17","author":"M El-Ansary","year":"2012","unstructured":"El-Ansary M, Saadi G, Abd El-Hamid SM. Mesenchymal stem cells are a rescue approach for recovery of deteriorating kidney function. Nephrology (Carlton). 2012;17(7):650\u20137.","journal-title":"Nephrology (Carlton)"},{"issue":"12","key":"4029_CR26","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.3727\/096368911X582769c","volume":"22","author":"D Wang","year":"2013","unstructured":"Wang D, Zhang H, Liang J, et al. Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant. 2013;22(12):2267\u201377.","journal-title":"Cell Transplant"},{"key":"4029_CR27","doi-asserted-by":"crossref","unstructured":"Wang D, Li J, Zhang Y, et al. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther. 2014;16(2):R79.","DOI":"10.1186\/ar4520"},{"issue":"11","key":"4029_CR28","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s10067-014-2754-4","volume":"33","author":"F Gu","year":"2014","unstructured":"Gu F, Wang D, Zhang H, et al. Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy. Clin Rheumatol. 2014;33(11):1611\u20139.","journal-title":"Clin Rheumatol"},{"key":"4029_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ebiom.2016.09.011","volume":"12","author":"DK Packham","year":"2016","unstructured":"Packham DK, Fraser IR, Kerr PG, Segal KR. Allogeneic Mesenchymal Precursor Cells (MPC) in Diabetic Nephropathy: A Randomized, Placebo-controlled. Dose Escalation Study EBioMedicine. 2016;12:263\u20139.","journal-title":"Dose Escalation Study EBioMedicine"},{"issue":"8","key":"4029_CR30","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1136\/annrheumdis-2017-211073","volume":"76","author":"D Deng","year":"2017","unstructured":"Deng D, Zhang P, Guo Y, Lim TO. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann Rheum Dis. 2017;76(8):1436\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"4029_CR31","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1681\/ASN.2017020151","volume":"28","author":"A Saad","year":"2017","unstructured":"Saad A, Dietz AB, Herrmann SMS, et al. Autologous Mesenchymal Stem Cells Increase Cortical Perfusion in Renovascular Disease. J Am Soc Nephrol. 2017;28(9):2777\u201385.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"4029_CR32","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13287-017-0557-7","volume":"8","author":"A Makhlough","year":"2017","unstructured":"Makhlough A, Shekarchian S, Moghadasali R, et al. Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patients. Stem Cell Res Ther. 2017;8(1):116.","journal-title":"Stem Cell Res Ther"},{"issue":"13","key":"4029_CR33","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1177\/0961203318804922","volume":"27","author":"J Barbado","year":"2018","unstructured":"Barbado J, Tabera S, S\u00e1nchez A, Garc\u00eda-Sancho J. Therapeutic potential of allogeneic mesenchymal stromal cells transplantation for lupus nephritis. Lupus. 2018;27(13):2161\u20135.","journal-title":"Lupus"},{"issue":"5","key":"4029_CR34","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jcyt.2018.02.368","volume":"20","author":"A Makhlough","year":"2018","unstructured":"Makhlough A, Shekarchian S, Moghadasali R, et al. Bone marrow-mesenchymal stromal cell infusion in patients with chronic kidney disease: A safety study with 18 months of follow-up. Cytotherapy. 2018;20(5):660\u20139.","journal-title":"Cytotherapy"},{"issue":"1","key":"4029_CR35","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1038\/s41467-019-10491-8","volume":"10","author":"X Yuan","year":"2019","unstructured":"Yuan X, Qin X, Wang D, et al. Mesenchymal stem cell therapy induces FLT3L and CD1c(+) dendritic cells in systemic lupus erythematosus patients. Nat Commun. 2019;10(1):2498.","journal-title":"Nat Commun"},{"issue":"2","key":"4029_CR36","first-page":"103324","volume":"70","author":"A Ranjbar","year":"2022","unstructured":"Ranjbar A, Hassanzadeh H, Jahandoust F, et al. Allogeneic adipose-derived mesenchymal stromal cell transplantation for refractory lupus nephritis: Results of a phase I clinical trial. Curr Res Transl Med. 2022;70(2): 103324.","journal-title":"Curr Res Transl Med"},{"issue":"10","key":"4029_CR37","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1177\/09612033221111957","volume":"31","author":"S Chun","year":"2022","unstructured":"Chun S, Choi C-B, Kim MS, et al. Safety and tolerability of bone marrow-derived mesenchymal stem cells in lupus animal models and a phase I clinical trial in humans. Lupus. 2022;31(10):1245\u201353.","journal-title":"Lupus"},{"issue":"10","key":"4029_CR38","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1681\/ASN.0000000000000189","volume":"34","author":"N Perico","year":"2023","unstructured":"Perico N, Remuzzi G, Griffin MD, et al. Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM). J Am Soc Nephrol. 2023;34(10):1733\u201351.","journal-title":"J Am Soc Nephrol"},{"key":"4029_CR39","doi-asserted-by":"crossref","unstructured":"Vivarelli M, Colucci M, Algeri M, et al. A phase I study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndrome. JCI Insight. 2023;8(18):e169424.","DOI":"10.1172\/jci.insight.169424"},{"issue":"1","key":"4029_CR40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/stcltm\/szac080","volume":"12","author":"MH Carstens","year":"2023","unstructured":"Carstens MH, Garc\u00eda N, Mandayam S, et al. Safety of Stromal Vascular Fraction Cell Therapy for Chronic Kidney Disease of Unknown Cause (Mesoamerican Nephropathy). Stem Cells Transl Med. 2023;12(1):7\u201316.","journal-title":"Stem Cells Transl Med"},{"issue":"4","key":"4029_CR41","first-page":"393","volume":"3","author":"AJ Friedenstein","year":"1970","unstructured":"Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 1970;3(4):393\u2013403.","journal-title":"Cell Tissue Kinet"},{"issue":"9","key":"4029_CR42","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/term.2914","volume":"13","author":"C Brown","year":"2019","unstructured":"Brown C, McKee C, Bakshi S, et al. Mesenchymal stem cells: Cell therapy and regeneration potential. J Tissue Eng Regen Med. 2019;13(9):1738\u201355.","journal-title":"J Tissue Eng Regen Med"},{"key":"4029_CR43","doi-asserted-by":"crossref","unstructured":"Guadix JA, Lopez-Beas J, Clares B, Soriano-Ruiz JL, Zugaza JL, Galvez-Martin P. Principal criteria for evaluating the quality, safety and efficacy of hMSC-based products in clinical practice: current approaches and challenges. Pharmaceutics. 2019;11(11):552.","DOI":"10.3390\/pharmaceutics11110552"},{"issue":"10","key":"4029_CR44","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.stem.2021.09.006","volume":"28","author":"M Krampera","year":"2021","unstructured":"Krampera M, Le Blanc K. Mesenchymal stromal cells: Putative microenvironmental modulators become cell therapy. Cell Stem Cell. 2021;28(10):1708\u201325.","journal-title":"Cell Stem Cell"},{"key":"4029_CR45","doi-asserted-by":"crossref","unstructured":"Arthur A, Gronthos S. Clinical application of bone marrow mesenchymal stem\/stromal cells to repair skeletal tissue. Int J Mol Sci. 2020;21(24):9759.","DOI":"10.3390\/ijms21249759"},{"issue":"1","key":"4029_CR46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/2162-3619-2-17","volume":"2","author":"Z Li","year":"2013","unstructured":"Li Z. CD133: a stem cell biomarker and beyond. Exp Hematol Oncol. 2013;2(1):17.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"4029_CR47","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13287-018-0914-1","volume":"9","author":"S Mohamed-Ahmed","year":"2018","unstructured":"Mohamed-Ahmed S, Fristad I, Lie SA, et al. Adipose-derived and bone marrow mesenchymal stem cells: a donor-matched comparison. Stem Cell Res Ther. 2018;9(1):168.","journal-title":"Stem Cell Res Ther"},{"issue":"Suppl 1","key":"4029_CR48","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.5213\/inj.1734856.428","volume":"21","author":"I Han","year":"2017","unstructured":"Han I, Kwon BS, Park HK, Kim KS. Differentiation Potential of Mesenchymal Stem Cells Is Related to Their Intrinsic Mechanical Properties. Int Neurourol J. 2017;21(Suppl 1):S24-31.","journal-title":"Int Neurourol J"},{"key":"4029_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actbio.2020.04.035","volume":"110","author":"IA Deus","year":"2020","unstructured":"Deus IA, Mano JF, Custodio CA. Perinatal tissues and cells in tissue engineering and regenerative medicine. Acta Biomater. 2020;110:1\u201314.","journal-title":"Acta Biomater"},{"issue":"2","key":"4029_CR50","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.exphem.2015.10.009","volume":"44","author":"K Mareschi","year":"2016","unstructured":"Mareschi K, Castiglia S, Sanavio F, et al. Immunoregulatory effects on T lymphocytes by human mesenchymal stromal cells isolated from bone marrow, amniotic fluid, and placenta. Exp Hematol. 2016;44(2):138-150 e1.","journal-title":"Exp Hematol."},{"issue":"1","key":"4029_CR51","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jcyt.2020.09.004","volume":"23","author":"VT Hoang","year":"2021","unstructured":"Hoang VT, Trinh QM, Phuong DTM, et al. Standardized xeno- and serum-free culture platform enables large-scale expansion of high-quality mesenchymal stem\/stromal cells from perinatal and adult tissue sources. Cytotherapy. 2021;23(1):88\u201399.","journal-title":"Cytotherapy"},{"issue":"1","key":"4029_CR52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40001-017-0258-9","volume":"22","author":"S Schneider","year":"2017","unstructured":"Schneider S, Unger M, van Griensven M, Balmayor ER. Adipose-derived mesenchymal stem cells from liposuction and resected fat are feasible sources for regenerative medicine. Eur J Med Res. 2017;22(1):17.","journal-title":"Eur J Med Res"},{"issue":"1","key":"4029_CR53","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41392-022-01134-4","volume":"7","author":"DM Hoang","year":"2022","unstructured":"Hoang DM, Pham PT, Bach TQ, et al. Stem cell-based therapy for human diseases. Signal Transduct Target Ther. 2022;7(1):272.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4029_CR54","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s13287-017-0716-x","volume":"8","author":"L Xu","year":"2017","unstructured":"Xu L, Liu Y, Sun Y, et al. Tissue source determines the differentiation potentials of mesenchymal stem cells: a comparative study of human mesenchymal stem cells from bone marrow and adipose tissue. Stem Cell Res Ther. 2017;8(1):275.","journal-title":"Stem Cell Res Ther"},{"key":"4029_CR55","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.bpobgyn.2015.08.014","volume":"31","author":"E Antoniadou","year":"2016","unstructured":"Antoniadou E, David AL. Placental stem cells. Best Pract Res Clin Obstet Gynaecol. 2016;31:13\u201329.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"4029_CR56","doi-asserted-by":"crossref","unstructured":"Ryu JS, Jeong EJ, Kim JY, et al. Application of mesenchymal stem cells in inflammatory and fibrotic diseases. Int J Mol Sci. 2020;21(21):8366.","DOI":"10.3390\/ijms21218366"},{"issue":"4","key":"4029_CR57","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315\u20137.","journal-title":"Cytotherapy"},{"issue":"2","key":"4029_CR58","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.canlet.2012.11.049","volume":"330","author":"Z Wang","year":"2013","unstructured":"Wang Z, Yan X. CD146, a multi-functional molecule beyond adhesion. Cancer Lett. 2013;330(2):150\u201362.","journal-title":"Cancer Lett"},{"issue":"1","key":"4029_CR59","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1038\/s41598-020-61167-z","volume":"10","author":"Y Petrenko","year":"2020","unstructured":"Petrenko Y, Vackova I, Kekulova K, et al. A Comparative Analysis of Multipotent Mesenchymal Stromal Cells derived from Different Sources, with a Focus on Neuroregenerative Potential. Sci Rep. 2020;10(1):4290.","journal-title":"Sci Rep"},{"issue":"1","key":"4029_CR60","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/jcmm.12168","volume":"18","author":"N Espagnolle","year":"2014","unstructured":"Espagnolle N, Guilloton F, Deschaseaux F, Gadelorge M, Sensebe L, Bourin P. CD146 expression on mesenchymal stem cells is associated with their vascular smooth muscle commitment. J Cell Mol Med. 2014;18(1):104\u201314.","journal-title":"J Cell Mol Med"},{"key":"4029_CR61","doi-asserted-by":"crossref","unstructured":"Veceric-Haler Z, Kojc N, Wechtersbach K, Perse M, Erman A. Cobalt ferrite magnetic nanoparticles for tracing mesenchymal stem cells in tissue: a preliminary study. Int J Mol Sci. 2022;23(15):8738.","DOI":"10.3390\/ijms23158738"},{"issue":"6","key":"4029_CR62","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1002\/stem.2614","volume":"35","author":"F Nitzsche","year":"2017","unstructured":"Nitzsche F, M\u00fcller C, Lukomska B, Jolkkonen J, Deten A, Boltze J. Concise Review: MSC Adhesion Cascade-Insights into Homing and Transendothelial Migration. Stem Cells. 2017;35(6):1446\u201360.","journal-title":"Stem Cells"},{"issue":"3","key":"4029_CR63","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1053\/j.ajkd.2021.12.011","volume":"80","author":"S Kant","year":"2022","unstructured":"Kant S, Kronbichler A, Geetha D. Principles of Immunosuppression in the Management of Kidney Disease: Core Curriculum 2022. Am J Kidney Dis. 2022;80(3):393\u2013405.","journal-title":"Am J Kidney Dis"},{"key":"4029_CR64","first-page":"4273107","volume":"2018","author":"HK Lee","year":"2018","unstructured":"Lee HK, Kim KH, Kim HS, et al. Effect of a Combination of Prednisone or Mycophenolate Mofetil and Mesenchymal Stem Cells on Lupus Symptoms in MRL. Faslpr Mice Stem Cells International. 2018;2018:4273107.","journal-title":"Faslpr Mice Stem Cells International"},{"key":"4029_CR65","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.biopha.2017.10.114","volume":"97","author":"E Javorkova","year":"2018","unstructured":"Javorkova E, Vackova J, Hajkova M, et al. The effect of clinically relevant doses of immunosuppressive drugs on human mesenchymal stem cells. Biomed Pharmacother. 2018;97:402\u201311.","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"4029_CR66","first-page":"5056","volume":"9","author":"W Fan","year":"2017","unstructured":"Fan W, Li J, Chen J, Zhu L, Wang Y, Sun B, Hua B, Guo C, Yan Z. Aspirin inhibits the proliferation of synovium-derived mesenchymal stem cells by arresting the cell cycle in the G0\/G1 phase. Am J Transl Res. 2017Nov 15;9(11):5056\u201362.","journal-title":"Am J Transl Res"},{"issue":"6","key":"4029_CR67","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1365-2184.2009.00639.x","volume":"42","author":"L Deng","year":"2009","unstructured":"Deng L, Hu S, Baydoun AR, Chen J, Chen X, Cong X. Aspirin induces apoptosis in mesenchymal stem cells requiring Wnt\/\u03b2-catenin pathway. Cell Prolif. 2009;42(6):721\u201330.","journal-title":"Cell Prolif"},{"issue":"34","key":"4029_CR68","doi-asserted-by":"publisher","first-page":"7153","DOI":"10.1039\/C7TB01732D","volume":"5","author":"Y Li","year":"2017","unstructured":"Li Y, Luo Z, Xu X, et al. Aspirin enhances the osteogenic and anti-inflammatory effects of human mesenchymal stem cells on osteogenic BFP-1 peptide-decorated substrates. Journal of Materials Chemistry B. 2017;5(34):7153\u201363.","journal-title":"Journal of Materials Chemistry B"},{"key":"4029_CR69","doi-asserted-by":"crossref","unstructured":"Cao Y, Xiong J, Mei S, et al. Aspirin promotes bone marrow mesenchymal stem cell-based calvarial bone regeneration in mini swine. Stem Cell Res Ther. 2015;6:210.","DOI":"10.1186\/s13287-015-0200-4"},{"key":"4029_CR70","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ejphar.2018.03.016","volume":"827","author":"W Hao","year":"2018","unstructured":"Hao W, Shi S, Zhou S, Wang X, Nie S. Aspirin inhibits growth and enhances cardiomyocyte differentiation of bone marrow mesenchymal stem cells. Eur J Pharmacol. 2018;827:198\u2013207.","journal-title":"Eur J Pharmacol"},{"key":"4029_CR71","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.biocel.2018.02.010","volume":"98","author":"Y Zhan","year":"2018","unstructured":"Zhan Y, He Z, Liu X, et al. Aspirin-induced attenuation of adipogenic differentiation of bone marrow mesenchymal stem cells is accompanied by the disturbed epigenetic modification. Int J Biochem Cell Biol. 2018;98:29\u201342.","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"4029_CR72","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1186\/s13287-021-02609-x","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, Yi H, Song Y. The safety of MSC therapy over the past 15 years: a meta-analysis. Stem Cell Res Ther. 2021;12(1):545.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"4029_CR73","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1634\/stemcells.2005-0403","volume":"24","author":"M Miura","year":"2006","unstructured":"Miura M, Miura Y, Padilla-Nash HM, et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells. 2006;24(4):1095\u2013103.","journal-title":"Stem Cells"},{"key":"4029_CR74","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.3389\/fimmu.2018.01359","volume":"9","author":"N Perico","year":"2018","unstructured":"Perico N, Casiraghi F, Todeschini M, et al. Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy. Front Immunol. 2018;9:1359.","journal-title":"Front Immunol"},{"key":"4029_CR75","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cytogfr.2024.01.004","volume":"76","author":"M Taheri","year":"2024","unstructured":"Taheri M, Tehrani HA, Dehghani S, et al. Signaling crosstalk between mesenchymal stem cells and tumor cells: Implications for tumor suppression or progression. Cytokine Growth Factor Rev. 2024;76:30\u201347.","journal-title":"Cytokine Growth Factor Rev"},{"key":"4029_CR76","doi-asserted-by":"crossref","unstructured":"Lin Z, Wu Y, Xu Y, Li G, Li Z, Liu T. Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential. Mol Cancer. 2022;21(1):179.","DOI":"10.1186\/s12943-022-01650-5"},{"issue":"2","key":"4029_CR77","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nm1703","volume":"14","author":"R Sackstein","year":"2008","unstructured":"Sackstein R, Merzaban JS, Cain DW, et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med. 2008;14(2):181\u20137.","journal-title":"Nat Med"},{"issue":"21","key":"4029_CR78","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1161\/01.CIR.0000147780.30124.CF","volume":"110","author":"JD Abbott","year":"2004","unstructured":"Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, Giordano FJ. Stromal Cell-Derived Factor-1\u03b1 Plays a Critical Role in Stem Cell Recruitment to the Heart After Myocardial Infarction but Is Not Sufficient to Induce Homing in the Absence of Injury. Circulation. 2004;110(21):3300\u20135.","journal-title":"Circulation"},{"issue":"1","key":"4029_CR79","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/sctm.17-0172","volume":"7","author":"ME Mayorga","year":"2018","unstructured":"Mayorga ME, Kiedrowski M, McCallinhart P, et al. Role of SDF-1:CXCR4 in Impaired Post-Myocardial Infarction Cardiac Repair in Diabetes. Stem Cells Transl Med. 2018;7(1):115\u201324.","journal-title":"Stem Cells Transl Med"},{"issue":"6","key":"4029_CR80","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.stem.2008.03.003","volume":"2","author":"F Belema-Bedada","year":"2008","unstructured":"Belema-Bedada F, Uchida S, Martire A, Kostin S, Braun T. Efficient Homing of Multipotent Adult Mesenchymal Stem Cells Depends on FROUNT-Mediated Clustering of CCR2. Cell Stem Cell. 2008;2(6):566\u201375.","journal-title":"Cell Stem Cell"},{"key":"4029_CR81","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.isci.2019.05.004","volume":"15","author":"M Ullah","year":"2019","unstructured":"Ullah M, Liu DD, Thakor AS. Mesenchymal Stromal Cell Homing: Mechanisms and Strategies for Improvement. iScience. 2019;15:421\u201338.","journal-title":"iScience"},{"issue":"46","key":"4029_CR82","doi-asserted-by":"publisher","first-page":"80235","DOI":"10.18632\/oncotarget.10288","volume":"8","author":"J Bayo","year":"2016","unstructured":"Bayo J, Real A, Fiore EJ, et al. IL-8, GRO and MCP-1 produced by hepatocellular carcinoma microenvironment determine the migratory capacity of human bone marrow-derived mesenchymal stromal cells without affecting tumor aggressiveness. Oncotarget. 2016;8(46):80235\u201348.","journal-title":"Oncotarget"},{"issue":"7","key":"4029_CR83","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1634\/stemcells.2007-0054","volume":"25","author":"AL Ponte","year":"2009","unstructured":"Ponte AL, Marais E, Gallay N, et al. The In Vitro Migration Capacity of Human Bone Marrow Mesenchymal Stem Cells: Comparison of Chemokine and Growth Factor Chemotactic Activities. Stem Cells. 2009;25(7):1737\u201345.","journal-title":"Stem Cells"},{"issue":"12","key":"4029_CR84","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.4252\/wjsc.v12.i12.1529","volume":"12","author":"A Gonzalez-Gonzalez","year":"2020","unstructured":"Gonzalez-Gonzalez A, Garcia-Sanchez D, Dotta M, Rodriguez-Rey JC, Perez-Campo FM. Mesenchymal stem cells secretome: The cornerstone of cell-free regenerative medicine. World J Stem Cells. 2020;12(12):1529\u201352.","journal-title":"World J Stem Cells"},{"key":"4029_CR85","doi-asserted-by":"publisher","first-page":"963689723116425","DOI":"10.1177\/09636897231164251","volume":"32","author":"F Chen","year":"2023","unstructured":"Chen F, Chen N, Xia C, et al. Mesenchymal Stem Cell Therapy in Kidney Diseases: Potential and Challenges. Cell Transplant. 2023;32:9636897231164252.","journal-title":"Cell Transplant"},{"key":"4029_CR86","doi-asserted-by":"crossref","unstructured":"Holvoet P. Aging and metabolic reprogramming of adipose-derived stem cells affect molecular mechanisms related to cardiovascular diseases. Cells. 2023;12(24):2785.","DOI":"10.3390\/cells12242785"},{"issue":"9","key":"4029_CR87","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/sctm.19-0446","volume":"9","author":"R Stavely","year":"2020","unstructured":"Stavely R, Nurgali K. The emerging antioxidant paradigm of mesenchymal stem cell therapy. Stem Cells Transl Med. 2020;9(9):985\u20131006.","journal-title":"Stem Cells Transl Med"},{"issue":"6","key":"4029_CR88","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41585-019-0169-3","volume":"16","author":"DZ Sun","year":"2019","unstructured":"Sun DZ, Abelson B, Babbar P, Damaser MS. Harnessing the mesenchymal stem cell secretome for regenerative urology. Nat Rev Urol. 2019;16(6):363\u201375.","journal-title":"Nat Rev Urol"},{"key":"4029_CR89","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jare.2022.05.012","volume":"45","author":"H Li","year":"2023","unstructured":"Li H, Dai H, Li J. Immunomodulatory properties of mesenchymal stromal\/stem cells: The link with metabolism. J Adv Res. 2023;45:15\u201329.","journal-title":"J Adv Res"},{"issue":"5","key":"4029_CR90","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1007\/s12015-023-10539-9","volume":"19","author":"G Yang","year":"2023","unstructured":"Yang G, Fan X, Liu Y, et al. Immunomodulatory Mechanisms and Therapeutic Potential of Mesenchymal Stem Cells. Stem Cell Rev Rep. 2023;19(5):1214\u201331.","journal-title":"Stem Cell Rev Rep"},{"issue":"2","key":"4029_CR91","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3109\/21691401.2014.968823","volume":"44","author":"A Rahimzadeh","year":"2016","unstructured":"Rahimzadeh A, Mirakabad FS, Movassaghpour A, et al. Biotechnological and biomedical applications of mesenchymal stem cells as a therapeutic system. Artif Cells Nanomed Biotechnol. 2016;44(2):559\u201370.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"4029_CR92","doi-asserted-by":"crossref","unstructured":"Trigo CM, Rodrigues JS, Cam\u00f5es SP, Sol\u00e1 S, Miranda JP. Mesenchymal stem cell secretome for regenerative medicine: Where do we stand? J Adv Res. 2024;S2090-1232(24):00181\u20134.","DOI":"10.1016\/j.jare.2024.05.004"},{"key":"4029_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2019.03.016","volume":"285","author":"AS Moghaddam","year":"2019","unstructured":"Moghaddam AS, Afshari JT, Esmaeili SA, Saburi E, Joneidi Z, Momtazi-Borojeni AA. Cardioprotective microRNAs: Lessons from stem cell-derived exosomal microRNAs to treat cardiovascular disease. Atherosclerosis. 2019;285:1\u20139.","journal-title":"Atherosclerosis"},{"issue":"3","key":"4029_CR94","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1152\/physrev.00019.2015","volume":"96","author":"S Golpanian","year":"2016","unstructured":"Golpanian S, Wolf A, Hatzistergos KE, Hare JM. Rebuilding the Damaged Heart: Mesenchymal Stem Cells, Cell-Based Therapy, and Engineered Heart Tissue. Physiol Rev. 2016;96(3):1127\u201368.","journal-title":"Physiol Rev"},{"issue":"4","key":"4029_CR95","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41419-024-06620-x","volume":"15","author":"Z Chen","year":"2024","unstructured":"Chen Z, Xia X, Yao M, et al. The dual role of mesenchymal stem cells in apoptosis regulation. Cell Death Dis. 2024;15(4):250.","journal-title":"Cell Death Dis"},{"issue":"6","key":"4029_CR96","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41419-021-03883-6","volume":"12","author":"Y Fu","year":"2021","unstructured":"Fu Y, Sui B, Xiang L, et al. Emerging understanding of apoptosis in mediating mesenchymal stem cell therapy. Cell Death Dis. 2021;12(6):596.","journal-title":"Cell Death Dis"},{"issue":"4","key":"4029_CR97","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41419-020-2490-4","volume":"11","author":"H Wei","year":"2020","unstructured":"Wei H, Xu Y, Chen Q, Chen H, Zhu X, Li Y. Mesenchymal stem cell-derived exosomal miR-223 regulates neuronal cell apoptosis. Cell Death Dis. 2020;11(4):290.","journal-title":"Cell Death Dis"},{"key":"4029_CR98","doi-asserted-by":"publisher","first-page":"1397954","DOI":"10.3389\/fcell.2024.1397954","volume":"12","author":"H Su","year":"2024","unstructured":"Su H, Wang Z, Zhou L, Liu D, Zhang N. Regulation of the Nrf2\/HO-1 axis by mesenchymal stem cells-derived extracellular vesicles: implications for disease treatment. Front Cell Dev Biol. 2024;12:1397954.","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"4029_CR99","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jama.2016.10924","volume":"316","author":"M Afkarian","year":"2016","unstructured":"Afkarian M, Zelnick LR, Hall YN, et al. Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988\u20132014. JAMA. 2016;316(6):602\u201310.","journal-title":"JAMA"},{"issue":"4","key":"4029_CR100","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41581-019-0234-4","volume":"16","author":"SCW Tang","year":"2020","unstructured":"Tang SCW, Yiu WH. Innate immunity in diabetic kidney disease. Nat Rev Nephrol. 2020;16(4):206\u201322.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"4029_CR101","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s13287-020-01852-y","volume":"11","author":"E Xiang","year":"2020","unstructured":"Xiang E, Han B, Zhang Q, et al. Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis. Stem Cell Res Ther. 2020;11(1):336.","journal-title":"Stem Cell Res Ther"},{"key":"4029_CR102","doi-asserted-by":"publisher","first-page":"121950","DOI":"10.1016\/j.lfs.2023.121950","volume":"329","author":"SA Kashani","year":"2023","unstructured":"Kashani SA, Navabi R, Amini A, et al. Immunomodulatory potential of human clonal mesenchymal stem cells and their extracellular vesicle subpopulations in an inflammatory-mediated diabetic Rhesus monkey model. Life Sci. 2023;329: 121950.","journal-title":"Life Sci"},{"issue":"9","key":"4029_CR103","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.2337\/db10-1181","volume":"60","author":"KI Woroniecka","year":"2011","unstructured":"Woroniecka KI, Park AS, Mohtat D, Thomas DB, Pullman JM, Susztak K. Transcriptome analysis of human diabetic kidney disease. Diabetes. 2011;60(9):2354\u201369.","journal-title":"Diabetes"},{"issue":"1","key":"4029_CR104","first-page":"20","volume":"4","author":"WH Yiu","year":"2014","unstructured":"Yiu WH, Lin M, Tang SC. Toll-like receptor activation: from renal inflammation to fibrosis. Kidney Int Suppl 2011. 2014;4(1):20\u20135.","journal-title":"Kidney Int Suppl 2011."},{"issue":"1","key":"4029_CR105","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nm.1905","volume":"15","author":"K Nemeth","year":"2009","unstructured":"Nemeth K, Leelahavanichkul A, Yuen PST, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009;15(1):42\u20139.","journal-title":"Nat Med"},{"issue":"1\u20132","key":"4029_CR106","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.mce.2014.03.004","volume":"388","author":"X Gao","year":"2014","unstructured":"Gao X, Song L, Shen K, et al. Bone marrow mesenchymal stem cells promote the repair of islets from diabetic mice through paracrine actions. Mol Cell Endocrinol. 2014;388(1\u20132):41\u201350.","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"4029_CR107","doi-asserted-by":"publisher","first-page":"926","DOI":"10.2337\/db14-1042","volume":"64","author":"AT Ji","year":"2015","unstructured":"Ji AT, Chang YC, Fu YJ, Lee OK, Ho JH. Niche-dependent regulations of metabolic balance in high-fat diet-induced diabetic mice by mesenchymal stromal cells. Diabetes. 2015;64(3):926\u201336.","journal-title":"Diabetes"},{"issue":"1","key":"4029_CR108","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s13287-022-02927-8","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu Y, Chen J, Liang H, et al. Human umbilical cord-derived mesenchymal stem cells not only ameliorate blood glucose but also protect vascular endothelium from diabetic damage through a paracrine mechanism mediated by MAPK\/ERK signaling. Stem Cell Res Ther. 2022;13(1):258.","journal-title":"Stem Cell Res Ther"},{"key":"4029_CR109","doi-asserted-by":"crossref","unstructured":"Han X, Wang J, Li R, et al. Placental mesenchymal stem cells alleviate podocyte injury in diabetic kidney disease by modulating mitophagy via the SIRT1-PGC-1alpha-TFAM pathway. Int J Mol Sci. 2023;24(5):4696.","DOI":"10.3390\/ijms24054696"},{"key":"4029_CR110","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.freeradbiomed.2021.07.026","volume":"173","author":"A Ali","year":"2021","unstructured":"Ali A, Shibu MA, Kuo C-H, et al. CHIP-overexpressing Wharton\u2019s jelly-derived mesenchymal stem cells attenuate hyperglycemia-induced oxidative stress-mediated kidney injuries in diabetic rats. Free Radical Biol Med. 2021;173:70\u201380.","journal-title":"Free Radical Biol Med"},{"issue":"1","key":"4029_CR111","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12967-017-1253-1","volume":"15","author":"Y Jiang","year":"2017","unstructured":"Jiang Y, Zhang W, Xu S, et al. Transplantation of human fetal pancreatic progenitor cells ameliorates renal injury in streptozotocin-induced diabetic nephropathy. J Transl Med. 2017;15(1):147.","journal-title":"J Transl Med"},{"issue":"2","key":"4029_CR112","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1365-2249.2008.03758.x","volume":"154","author":"M Tucci","year":"2008","unstructured":"Tucci M, Lombardi L, Richards HB, Dammacco F, Silvestris F. Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clin Exp Immunol. 2008;154(2):247\u201354.","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"4029_CR113","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nri3209","volume":"12","author":"K Le Blanc","year":"2012","unstructured":"Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol. 2012;12(5):383\u201396.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"4029_CR114","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/ndt\/gfy195","volume":"34","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Niu L, Tang X, et al. Mesenchymal stem cells prevent podocyte injury in lupus-prone B6. MRL-Faslpr mice via polarizing macrophage into an anti-inflammatory phenotype. Nephrology Dialysis Transplantation. 2019;34(4):597\u2013605.","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"4029_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3727\/096368915X688173","volume":"25","author":"E Jang","year":"2016","unstructured":"Jang E, Jeong M, Kim S, et al. Infusion of Human Bone Marrow-Derived Mesenchymal Stem Cells Alleviates Autoimmune Nephritis in a Lupus Model by Suppressing Follicular Helper T-Cell Development. Cell Transplant. 2016;25(1):1\u201315.","journal-title":"Cell Transplant"},{"issue":"3","key":"4029_CR116","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1182\/blood-2007-02-074997","volume":"111","author":"GM Spaggiari","year":"2008","unstructured":"Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 2008;111(3):1327\u201333.","journal-title":"Blood"},{"key":"4029_CR117","doi-asserted-by":"publisher","first-page":"843192","DOI":"10.3389\/fimmu.2022.843192","volume":"13","author":"J Li","year":"2022","unstructured":"Li J, Luo M, Li B, et al. Immunomodulatory Activity of Mesenchymal Stem Cells in Lupus Nephritis: Advances and Applications. Front Immunol. 2022;13: 843192.","journal-title":"Front Immunol"},{"key":"4029_CR118","doi-asserted-by":"crossref","unstructured":"Zhou T, Liao C, Li H-Y, Lin W, Lin S, Zhong H. Efficacy of mesenchymal stem cells in animal models of lupus nephritis: a meta-analysis. Stem Cell Res Ther. 2020;11(1):48.","DOI":"10.1186\/s13287-019-1538-9"},{"key":"4029_CR119","doi-asserted-by":"crossref","unstructured":"Yin L, Yang Z, Wu Y, et al. Label-free separation of mesenchymal stem cell subpopulations with distinct differentiation potencies and paracrine effects. Biomaterials. 2020;240:119881.","DOI":"10.1016\/j.biomaterials.2020.119881"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04029-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04029-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04029-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T11:53:17Z","timestamp":1741348397000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04029-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":119,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4029"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04029-y","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"9 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}